Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 Your complete learning platform for speakers of 21 languages: Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Breast Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 162 articles: HTML format

Single Articles

April 2026
1. KHOR S, Yu K, Fedorenko CR, Ramsey S, et al
   Financial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screening.
   J Clin Oncol. 2026;44:1130-1138.
   PubMed     Abstract available
   
   
   
2. LOIBL S, Untch M, Huober J, Schaser V, et al
   Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial.
   J Clin Oncol. 2026 Apr 20:JCO2502311. doi: 10.1200/JCO-25-02311.
   PubMed     Abstract available
   
   
   
3. CATHCART-RAKE EJ, Thao V, Le-Rademacher J, Helfinstine DA, et al
   Nationwide Mammographic Screening Among a Large Population of Underserved Subgroups.
   J Clin Oncol. 2026;44:981-991.
   PubMed     Abstract available
   
   
   
4. GANDHI A, Howell SJ, Harkness EF, Woodward E, et al
   Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers.
   J Clin Oncol. 2026;44:874-882.
   PubMed     Abstract available
   
   
   March 2026
5. BOSSERMAN LD, Dizon DS
   Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition.
   J Clin Oncol. 2026 Mar 31:JCO2503121. doi: 10.1200/JCO-25-03121.
   PubMed    
   
   
   
6. SCHNEIDER BP, Stover DG
   From Prognosis to Action: Circulating Tumor DNA and the Next Phase of Risk Stratification in Triple-Negative Breast Cancer.
   J Clin Oncol. 2026 Mar 18:JCO2600103. doi: 10.1200/JCO-26-00103.
   PubMed    
   
   
   
7. HUNTER NB, Parsons HA, Cope L, Canzoniero JV, et al
   The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
   J Clin Oncol. 2026 Mar 10:JCO2502934. doi: 10.1200/JCO-25-02934.
   PubMed     Abstract available
   
   
   
8. HURVITZ SA, Layman RM, Curigliano G, Andre F, et al
   VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
   J Clin Oncol. 2026 Mar 9:JCO2502643. doi: 10.1200/JCO-25-02643.
   PubMed     Abstract available
   
   
   
9. KIM J, Munster PN
   Cracks in the Estrogen Carcinogenesis of Breast Cancer.
   J Clin Oncol. 2026 Mar 5:JCO2503084. doi: 10.1200/JCO-25-03084.
   PubMed    
   
   
   
10. LI T, Zhou T, Wang B, Tao Z, et al
    Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).
    J Clin Oncol. 2026 Mar 4:JCO2502021. doi: 10.1200/JCO-25-02021.
    PubMed     Abstract available
    
    
    February 2026
11. APOSTOL AI, Gronwald J, Cybulski C, Kim RH, et al
    Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.
    J Clin Oncol. 2026 Feb 28:JCO2501648. doi: 10.1200/JCO-25-01648.
    PubMed     Abstract available
    
    
    
12. TARANTINO P
    Erratum: Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2026 Feb 9:JCO2600219. doi: 10.1200/JCO-26-00219.
    PubMed    
    
    
    January 2026
13. TUNG NM, Robson ME, Li T, Nanda R, et al
    TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.
    J Clin Oncol. 2026 Jan 28:JCO2502075. doi: 10.1200/JCO-25-02075.
    PubMed     Abstract available
    
    
    
14. HILSENBECK SG, Thompson AM
    Windows of Opportunity in Breast Cancer: Learning More From Fewer Patients in a Shorter Time.
    J Clin Oncol. 2026 Jan 23:JCO2502714. doi: 10.1200/JCO-25-02714.
    PubMed    
    
    
    
15. TARANTINO P
    Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2026 Jan 23:JCO2502855. doi: 10.1200/JCO-25-02855.
    PubMed    
    
    
    
16. GAO HF, Ye GL, Lin Y, Huang Q, et al
    Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial.
    J Clin Oncol. 2026 Jan 23:JCO2502176. doi: 10.1200/JCO-25-02176.
    PubMed     Abstract available
    
    
    
17. VALENZA C, Nixon NA, Cheung WY, Tolaney SM, et al
    Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2026 Jan 22:JCO2502942. doi: 10.1200/JCO-25-02942.
    PubMed    
    
    
    
18. BANYS-PALUCHOWSKI M, Hartmann S, de Boniface J, Gentilini OD, et al
    Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study.
    J Clin Oncol. 2026 Jan 21:JCO2501921. doi: 10.1200/JCO-25-01921.
    PubMed     Abstract available
    
    
    
19. ROBERTSON JFR, Gogitidze T, Katashvili Z, Rocha JEB, et al
    Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.
    J Clin Oncol. 2026 Jan 16:JCO2501548. doi: 10.1200/JCO-25-01548.
    PubMed     Abstract available
    
    
    
20. VALENZA C, Zheng Y, Milano M, Trapani D, et al
    Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.
    J Clin Oncol. 2026 Jan 15:JCO2501660. doi: 10.1200/JCO-25-01660.
    PubMed     Abstract available
    
    
    
21. DOMCHEK SM
    Therapeutic Considerations in Early-Stage, Estrogen Receptor-Positive, BRCA-Associated Breast Cancer.
    J Clin Oncol. 2026 Jan 5:JCO2502428. doi: 10.1200/JCO-25-02428.
    PubMed    
    
    
    December 2025
22. DIERAS V, Curigliano G, Martin M, Lerebours F, et al
    HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
    J Clin Oncol. 2025 Dec 10:101200JCO2502600. doi: 10.1200/JCO-25-02600.
    PubMed     Abstract available
    
    
    
23. CHEN X, Huang J, Shi H, Zhu J, et al
    Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
    J Clin Oncol. 2025 Dec 9:JCO2502412. doi: 10.1200/JCO-25-02412.
    PubMed     Abstract available
    
    
    November 2025
24. LI JJ, Zhang WJ, Zeng XH, Zhang QY, et al
    Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial.
    J Clin Oncol. 2025 Nov 25:JCO2501153. doi: 10.1200/JCO-25-01153.
    PubMed     Abstract available
    
    
    
25. YADAV RK, Miller KD
    Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard?
    J Clin Oncol. 2025 Nov 21:JCO2502336. doi: 10.1200/JCO-25-02336.
    PubMed    
    
    
    
26. DE LAURENTIIS M, Buonaiuto R, Buono G, Caputo R, et al
    In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast Cancer.
    J Clin Oncol. 2025 Nov 7:JCO2501440. doi: 10.1200/JCO-25-01440.
    PubMed    
    
    
    October 2025
27. JIMENEZ RB, Abdou Y, Anderson P, Barry P, et al
    Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline.
    J Clin Oncol. 2025;43:3292-3311.
    PubMed     Abstract available
    
    
    
28. LIN JK, Niu J, Giordano SH, Li P, et al
    Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers.
    J Clin Oncol. 2025;43:3254-3265.
    PubMed     Abstract available
    
    
    
29. GUPTA S, Nair N, Hawaldar RW, Joshi S, et al
    Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.
    J Clin Oncol. 2025 Oct 20:JCO2501023. doi: 10.1200/JCO-25-01023.
    PubMed     Abstract available
    
    
    
30. KAVIANI A, Bourque JM, Farazmand B, Salmon RJ, et al
    Beyond the Trials: Real-World Considerations for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer.
    J Clin Oncol. 2025 Oct 13:JCO2501630. doi: 10.1200/JCO-25-01630.
    PubMed    
    
    
    
31. BIDARD FC, Gessain G, Bachelot T, Frechin L, et al
    Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
    J Clin Oncol. 2025 Oct 7:JCO2502272. doi: 10.1200/JCO-25-02272.
    PubMed    
    
    
    September 2025
32. DICKERSON JC, Caswell-Jin JL, Riaz F, Goldhaber-Fiebert JD, et al
    Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.
    J Clin Oncol. 2025 Sep 24:JCO2501879. doi: 10.1200/JCO-25-01879.
    PubMed    
    
    
    
33. WU J, Ma D, Xing Z
    Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.
    J Clin Oncol. 2025 Sep 24:JCO2501656. doi: 10.1200/JCO-25-01656.
    PubMed    
    
    
    
34. CONFORTI F, Merlo F, Pala L, Canzian J, et al
    Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.
    J Clin Oncol. 2025 Sep 17:JCO2501148. doi: 10.1200/JCO-25-01148.
    PubMed    
    
    
    
35. WINCHESTER DJ
    Reply to: Response to Neoadjuvant Chemotherapy and Breast Cancer Subtypes.
    J Clin Oncol. 2025 Sep 15:JCO2501972. doi: 10.1200/JCO-25-01972.
    PubMed    
    
    
    
36. MARTIN M
    Response to Neoadjuvant Chemotherapy and Breast Cancer Subtypes.
    J Clin Oncol. 2025 Sep 15:JCO2501342. doi: 10.1200/JCO-25-01342.
    PubMed    
    
    
    
37. PATEL BK, Carnahan MB, Northfelt D, Anderson K, et al
    Erratum: Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.
    J Clin Oncol. 2025 Sep 2:JCO2501993. doi: 10.1200/JCO-25-01993.
    PubMed    
    
    
    August 2025
38. ERGUN Y
    CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer.
    J Clin Oncol. 2025 Aug 28:JCO2500836. doi: 10.1200/JCO-25-00836.
    PubMed    
    
    
    
39. FREEMAN JQ, Nanda R, Howard FM
    Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer.
    J Clin Oncol. 2025 Aug 28:JCO2501176. doi: 10.1200/JCO-25-01176.
    PubMed    
    
    
    
40. GOETZ MP, Choong GM, Hoskin TL, Boughey JC, et al
    Reply to: "Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer" and "CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer".
    J Clin Oncol. 2025 Aug 28:JCO2501688. doi: 10.1200/JCO-25-01688.
    PubMed    
    
    
    
41. BIDARD FC, Gessain G, Bachelot T, Frechin L, et al
    Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
    J Clin Oncol. 2025 Aug 22:JCO2500742. doi: 10.1200/JCO-25-00742.
    PubMed     Abstract available
    
    
    
42. WEDAM S, Narayan P, Gittleman H, Cheng J, et al
    US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast
    J Clin Oncol. 2025 Aug 22:JCO2500663. doi: 10.1200/JCO-25-00663.
    PubMed     Abstract available
    
    
    
43. CAI L, Pfob A, Barr RG, Duda V, et al
    Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis.
    J Clin Oncol. 2025 Aug 20:JCO2402681. doi: 10.1200/JCO-24-02681.
    PubMed     Abstract available
    
    
    
44. JERZAK KJ, Warner E, Knisely JPS, Sahgal A, et al
    Brain Imaging Surveillance for Patients With Metastatic Breast Cancer: A Randomized Clinical Trial Is Required to Guide Practice.
    J Clin Oncol. 2025 Aug 13:JCO2500356. doi: 10.1200/JCO-25-00356.
    PubMed    
    
    
    
45. GAO JJ, Prowell TM, Gittleman H, Cheng J, et al
    US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.
    J Clin Oncol. 2025 Aug 11:JCO2500167. doi: 10.1200/JCO-25-00167.
    PubMed     Abstract available
    
    
    
46. DILAWARI A, Zhang H, Shah M, Gao X, et al
    US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Recep
    J Clin Oncol. 2025 Aug 5:JCO2500812. doi: 10.1200/JCO-25-00812.
    PubMed     Abstract available
    
    
    July 2025
47. PUSZTAI L, Rozenblit M, Dubsky P, Bachelot T, et al
    Erratum: De Novo Oligometastatic Breast Cancer.
    J Clin Oncol. 2025 Jul 21:JCO2501626. doi: 10.1200/JCO-25-01626.
    PubMed    
    
    
    
48. PECCATORI FA, Niman SM, Partridge AH, Ruggeri M, et al
    Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.
    J Clin Oncol. 2025 Jul 9:JCO2402697. doi: 10.1200/JCO-24-02697.
    PubMed     Abstract available
    
    
    
49. NIRAULA S
    Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials.
    J Clin Oncol. 2025 Jul 2:JCO2500325. doi: 10.1200/JCO-25-00325.
    PubMed    
    
    
    
50. LI XJ, Yu G, Li GF
    Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer.
    J Clin Oncol. 2025 Jul 2:JCO2500502. doi: 10.1200/JCO-25-00502.
    PubMed    
    
    
    
51. CONFORTI F, Bagnardi V, Sala I
    Reply to: "Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials" and "Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer".
    J Clin Oncol. 2025 Jul 2:JCO2501041. doi: 10.1200/JCO-25-01041.
    PubMed    
    
    
    May 2025
52. DICKERSON JC, Moen MT, Nielsen P Jr, Riaz F, et al
    Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer.
    J Clin Oncol. 2025 May 21:JCO2401960. doi: 10.1200/JCO-24-01960.
    PubMed     Abstract available
    
    
    
53. VEENSTRA CM, Abrahamse P, Hamilton AS, Ward KC, et al
    Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM, CHEK2, or PALB2.
    J Clin Oncol. 2025;43:1587-1596.
    PubMed     Abstract available
    
    
    April 2025
54. LLOMBART-CUSSAC A, Harper-Wynne C, Perello A, Hennequin A, et al
    Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.
    J Clin Oncol. 2025 Apr 28:JCO2401865. doi: 10.1200/JCO-24-01865.
    PubMed     Abstract available
    
    
    
55. TESCH ME, Partridge AH
    Can Improving Adjuvant Endocrine Therapy Persistence Improve Survival Outcomes for Patients With Early-Stage Breast Cancer?
    J Clin Oncol. 2025 Apr 16:JCO2500371. doi: 10.1200/JCO-25-00371.
    PubMed    
    
    
    
56. TANNOCK IF, Khan QJ, Fojo T
    Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.
    J Clin Oncol. 2025 Apr 14:JCO2402683. doi: 10.1200/JCO-24-02683.
    PubMed    
    
    
    
57. WINCHESTER DJ, Singh L, Edge SB, Allison KH, et al
    Novel Postneoadjuvant Prognostic Breast Cancer Staging System.
    J Clin Oncol. 2025 Apr 11:JCO2401739. doi: 10.1200/JCO-24-01739.
    PubMed     Abstract available
    
    
    
58. CHOONG GM, Hoskin TL, Boughey JC, Ingle JN, et al
    Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer.
    J Clin Oncol. 2025 Apr 11:JCO2402263. doi: 10.1200/JCO-24-02263.
    PubMed     Abstract available
    
    
    
59. YAMAMOTO Y, Iwata H, Saji S, Takahashi M, et al
    Erratum: Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.
    J Clin Oncol. 2025 Apr 11:JCO2500722. doi: 10.1200/JCO-25-00722.
    PubMed    
    
    
    
60. PARK KU, Somerfield MR, Anne N, Brackstone M, et al
    Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2025 Apr 10:JCO2500099. doi: 10.1200/JCO-25-00099.
    PubMed     Abstract available
    
    
    March 2025
61. BARDIA A, Pistilli B, Rugo H
    Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer.
    J Clin Oncol. 2025 Mar 28:JCO2402833. doi: 10.1200/JCO-24-02833.
    PubMed    
    
    
    
62. WANG X, Ludmir EB, Wei LJ
    Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer.
    J Clin Oncol. 2025 Mar 28:JCO2402207. doi: 10.1200/JCO-24-02207.
    PubMed    
    
    
    
63. GROHEUX D, Vaz SC, de Geus-Oei LF, Dibble EH, et al
    (18)F-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast Cancer.
    J Clin Oncol. 2025 Mar 25:JCO2401945. doi: 10.1200/JCO-24-01945.
    PubMed    
    
    
    
64. DUMAS E, Jochum F, Coussy F, Hamy AS, et al
    Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor-Positive Early Breast Cancer: A Nationwide Cohort Study.
    J Clin Oncol. 2025 Mar 5:JCO2401131. doi: 10.1200/JCO.24.01131.
    PubMed     Abstract available
    
    
    
65. MONTAGNA G, Laws A, Ferrucci M, Mrdutt MM, et al
    Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study.
    J Clin Oncol. 2025;43:810-820.
    PubMed     Abstract available
    
    
    February 2025
66. LAMBERTINI M, Blondeaux E, Tomasello LM, Agostinetto E, et al
    Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status.
    J Clin Oncol. 2025 Feb 24:JCO2401334. doi: 10.1200/JCO-24-01334.
    PubMed     Abstract available
    
    
    
67. ROBERTSON JFR, Shao Z, Noguchi S, Bondarenko I, et al
    Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy-Naive Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
    J Clin Oncol. 2025 Feb 7:JCO2500116. doi: 10.1200/JCO-25-00116.
    PubMed    
    
    
    January 2025
68. CONFORTI F, Nekljudova V, Sala I, Ascari R, et al
    Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.
    J Clin Oncol. 2025 Jan 30:JCO2401360. doi: 10.1200/JCO-24-01360.
    PubMed     Abstract available
    
    
    
69. YAMAMOTO Y, Iwata H, Saji S, Takahashi M, et al
    Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.
    J Clin Oncol. 2025 Jan 24:JCO2401673. doi: 10.1200/JCO-24-01673.
    PubMed     Abstract available
    
    
    
70. O'MEARA TA, Tarantino P
    Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the EMERALD Study.
    J Clin Oncol. 2025 Jan 22:JCO2402717. doi: 10.1200/JCO-24-02717.
    PubMed    
    
    
    
71. MAYERHOFER C, Freedman RA, Parsons HA, Partridge AH, et al
    Clonal Hematopoiesis in Women With Breast Cancer.
    J Clin Oncol. 2025 Jan 17:JCO2401848. doi: 10.1200/JCO-24-01848.
    PubMed     Abstract available
    
    
    
72. SCHOUTEN AEM, Hiensch AE, Frederix GWJ, Monninkhof EM, et al
    Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.
    J Clin Oncol. 2025 Jan 13:JCO2401441. doi: 10.1200/JCO-24-01441.
    PubMed     Abstract available
    
    
    
73. YAMASHITA T, Saji S, Takano T, Naito Y, et al
    Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
    J Clin Oncol. 2025 Jan 9:JCO2401888. doi: 10.1200/JCO-24-01888.
    PubMed     Abstract available
    
    
    
74. ROBERTSON JFR, Shao Z, Noguchi S, Bondarenko I, et al
    Fulvestrant Versus Anastrozole in Endocrine Therapy-Naive Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
    J Clin Oncol. 2025 Jan 7:JCO2400994. doi: 10.1200/JCO.24.00994.
    PubMed     Abstract available
    
    
    
75. MI L, Wei JC, Xu K, Gao J, et al
    Expanding the Horizon of MRONJ Research in Breast Cancer Bone Metastasis Treatments.
    J Clin Oncol. 2025 Jan 6:JCO2402205. doi: 10.1200/JCO-24-02205.
    PubMed    
    
    
    
76. HONG RX, Xu F, Xia W, Teng YE, et al
    Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-The Phase III MECCA Trial.
    J Clin Oncol. 2025 Jan 2:JCO2400938. doi: 10.1200/JCO.24.00938.
    PubMed     Abstract available
    
    
    
77. METZGER FILHO O, Ballman K, Campbell J, Liu M, et al
    Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.
    J Clin Oncol. 2025 Jan 2:JCO2401875. doi: 10.1200/JCO-24-01875.
    PubMed     Abstract available
    
    
    December 2024
78. KALINSKY K, Bianchini G, Hamilton E, Graff SL, et al
    Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial.
    J Clin Oncol. 2024 Dec 18:JCO2402086. doi: 10.1200/JCO-24-02086.
    PubMed     Abstract available
    
    
    
79. ZULEY ML, Bandos AI, Duffy SW, Logue D, et al
    Reply to: "Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits" and "Annual Versus Biennial Mammographic Screening".
    J Clin Oncol. 2024 Dec 17:JCO2402373. doi: 10.1200/JCO-24-02373.
    PubMed    
    
    
    
80. AUTIER P
    Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits.
    J Clin Oncol. 2024 Dec 17:JCO2401965. doi: 10.1200/JCO-24-01965.
    PubMed    
    
    
    
81. SPARANO JA
    Development and Validation of Data-Driven Estimates of Recurrence Risk and Treatment Benefit in Early Breast Cancer.
    J Clin Oncol. 2024 Dec 12:JCO2402452. doi: 10.1200/JCO-24-02452.
    PubMed    
    
    
    
82. PUSZTAI L, Hoag JR, Albain KS, Barlow WE, et al
    Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
    J Clin Oncol. 2024 Dec 2:JCO2401507. doi: 10.1200/JCO-24-01507.
    PubMed     Abstract available
    
    
    
83. SHEN G, Ren D, Zhao F, Wang M, et al
    Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial.
    J Clin Oncol. 2024;42:4051-4059.
    PubMed     Abstract available
    
    
    November 2024
84. 
    Erratum: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Stu
    J Clin Oncol. 2024 Nov 19:JCO2402470. doi: 10.1200/JCO-24-02470.
    PubMed    
    
    
    
85. 
    Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Yea
    J Clin Oncol. 2024 Nov 19:JCO2402469. doi: 10.1200/JCO-24-02469.
    PubMed    
    
    
    
86. AGOSTINETTO E, Caballero C, Ignatiadis M, Pop CF, et al
    Axillary Surgery for Patients With Residual Isolated Tumor Cells (ypN0i+) After Neoadjuvant Systemic Therapy for Early Breast Cancer.
    J Clin Oncol. 2024 Nov 12:JCO2401711. doi: 10.1200/JCO-24-01711.
    PubMed     Abstract available
    
    
    
87. GRINDA T, Burstein HJ
    Anthracyclines in Early Breast Cancer: The Long Goodbye.
    J Clin Oncol. 2024 Nov 5:JCO2401916. doi: 10.1200/JCO-24-01916.
    PubMed    
    
    
    October 2024
88. ALLEN I, Hassan H, Walburga Y, Huntley C, et al
    Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers.
    J Clin Oncol. 2024 Oct 29:JCO2401146. doi: 10.1200/JCO.24.01146.
    PubMed     Abstract available
    
    
    
89. WHITE AJ
    Growing Evidence for the Role of Air Pollution in Breast Cancer Development.
    J Clin Oncol. 2024 Oct 28:JCO2401987. doi: 10.1200/JCO-24-01987.
    PubMed    
    
    
    
90. MOSHER CE, Lee S, Addington EL, Park S, et al
    Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer.
    J Clin Oncol. 2024 Oct 25:JCO2400965. doi: 10.1200/JCO.24.00965.
    PubMed     Abstract available
    
    
    
91. TURNER N, Saura C, Aftimos P, van den Tweel E, et al
    Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
    J Clin Oncol. 2024 Oct 23:JCO2400529. doi: 10.1200/JCO.24.00529.
    PubMed     Abstract available
    
    
    
92. JENSEN MB, Balslev E, Knoop AS, Tuxen MK, et al
    Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial.
    J Clin Oncol. 2024 Oct 23:JCO2400836. doi: 10.1200/JCO.24.00836.
    PubMed     Abstract available
    
    
    
93. BARBI M, Gorman M, John VS
    Navigating Hormone Therapy in Postmenopausal Women: Balancing Symptom Relief With Cancer Risk.
    J Clin Oncol. 2024;42:3517-3522.
    PubMed     Abstract available
    
    
    
94. GOEL N, Hernandez A, Cole SW
    Social Genomic Determinants of Health: Understanding the Molecular Pathways by Which Neighborhood Disadvantage Affects Cancer Outcomes.
    J Clin Oncol. 2024;42:3618-3627.
    PubMed     Abstract available
    
    
    
95. BERGSTROM EN, Abbasi A, Diaz-Gay M, Galland L, et al
    Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.
    J Clin Oncol. 2024;42:3550-3560.
    PubMed     Abstract available
    
    
    
96. RASTOGI P, Bandos H, Lucas PC, van 't Veer LJ, et al
    Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
    J Clin Oncol. 2024;42:3561-3569.
    PubMed     Abstract available
    
    
    
97. THOMAS A, Mayer EL, DeMichele A, Harbeck N, et al
    Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer.
    J Clin Oncol. 2024 Oct 9:JCO2401080. doi: 10.1200/JCO.24.01080.
    PubMed     Abstract available
    
    
    
98. KIM DH, Theberge V, Parpia S, Kong I, et al
    OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer.
    J Clin Oncol. 2024 Oct 8:JCO2400600. doi: 10.1200/JCO.24.00600.
    PubMed     Abstract available
    
    
    
99. WU AH, Wu J, Tseng C, Stram DO, et al
    Air Pollution and Breast Cancer Incidence in the Multiethnic Cohort Study.
    J Clin Oncol. 2024 Oct 8:JCO2400418. doi: 10.1200/JCO.24.00418.
    PubMed     Abstract available
    
    
    
100. FUCHAO C, Jingyue S, Xiao W
     Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy.
     J Clin Oncol. 2024 Oct 4:JCO2401571. doi: 10.1200/JCO-24-01571.
     PubMed    
     
     
     
101. AL-SHAMSI HO, Abdelwahed N, Mokbel K
     Surveillance Systemic Imaging After Curative Intent for Breast Cancer: A Double Standard?
     J Clin Oncol. 2024 Oct 3:JCO2401186. doi: 10.1200/JCO.24.01186.
     PubMed    
     
     
     
102. PHILLIPS KA, Kotsopoulos J, Domchek SM, Terry MB, et al
     Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.
     J Clin Oncol. 2024 Oct 2:JCO2400176. doi: 10.1200/JCO.24.00176.
     PubMed     Abstract available
     
     
     September 2024
103. BICKELL NA, Nattinger AB, McGinley EL, Schymura MJ, et al
     The Effect on Travel Distance of a Statewide Regionalization Policy for Initial Breast Cancer Surgery.
     J Clin Oncol. 2024 Sep 30:JCO2302638. doi: 10.1200/JCO.23.02638.
     PubMed     Abstract available
     
     
     
104. YANG S
     Methodological Considerations for Ensuring Robustness in Exercise and Breast Cancer Recurrence Studies.
     J Clin Oncol. 2024 Sep 20:JCO2401299. doi: 10.1200/JCO-24-01299.
     PubMed    
     
     
     
105. WARREN LEG, Bellon JR
     Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
     J Clin Oncol. 2024;42:3167-3169.
     PubMed    
     
     
     
106. HAHN E, Sutradhar R, Paszat L, Nguyen L, et al
     Molecular Expression Assays Improve the Prediction of Local and Invasive Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.
     J Clin Oncol. 2024;42:3196-3206.
     PubMed     Abstract available
     
     
     
107. HO AY, Shiao S, Kobald SA, Chen J, et al
     PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
     J Clin Oncol. 2024 Sep 19:JCO2400003. doi: 10.1200/JCO.24.00003.
     PubMed     Abstract available
     
     
     
108. BHARDWAJ PV, Abdou Y
     Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies.
     J Clin Oncol. 2024 Sep 18:JCO2401295. doi: 10.1200/JCO-24-01295.
     PubMed     Abstract available
     
     
     
109. TORRES JM, Sodipo MO, Hopkins MF, Chandler PD, et al
     Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis.
     J Clin Oncol. 2024 Sep 17:JCO2302311. doi: 10.1200/JCO.23.02311.
     PubMed     Abstract available
     
     
     
110. LIU S, Hu R
     Insights and Limitations of the Study on Temporary Interruption of Endocrine Therapy and Assisted Reproductive Technology Use in Breast Cancer Survivors.
     J Clin Oncol. 2024 Sep 16:JCO2401227. doi: 10.1200/JCO-24-01227.
     PubMed    
     
     
     
111. WEN Z, Duan S, Liu H
     Advancing Fertility Preservation in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy: Societal and Psychological Implications.
     J Clin Oncol. 2024 Sep 16:JCO2401204. doi: 10.1200/JCO-24-01204.
     PubMed    
     
     
     
112. BARDIA A, Jhaveri K, Im SA, Pernas S, et al
     Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
     J Clin Oncol. 2024 Sep 12:JCO2400920. doi: 10.1200/JCO.24.00920.
     PubMed     Abstract available
     
     
     
113. LOIBL S, Jassem J, Sonnenblick A, Parlier D, et al
     Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
     J Clin Oncol. 2024 Sep 11:JCO2302505. doi: 10.1200/JCO.23.02505.
     PubMed     Abstract available
     
     
     
114. KANG D, Cho J, Zhao D, Kim J, et al
     Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial.
     J Clin Oncol. 2024;42:3115-3122.
     PubMed     Abstract available
     
     
     
115. JHAVERI KL, Lim E, Jeselsohn R, Ma CX, et al
     Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
     J Clin Oncol. 2024 Sep 6:JCO2302733. doi: 10.1200/JCO.23.02733.
     PubMed     Abstract available
     
     
     
116. JHAVERI KL, Accordino MK, Bedard PL, Cervantes A, et al
     Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
     J Clin Oncol. 2024 Sep 5:JCO2400110. doi: 10.1200/JCO.24.00110.
     PubMed     Abstract available
     
     
     
117. CLASEN SC, Miller ME
     How We Monitor Cardiac Health in Breast Cancer Survivors.
     J Clin Oncol. 2024 Sep 3:JCO2400757. doi: 10.1200/JCO.24.00757.
     PubMed     Abstract available
     
     
     August 2024
118. ZULEY ML, Bandos AI, Duffy SW, Logue D, et al
     Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival.
     J Clin Oncol. 2024 Aug 21:JCO2400285. doi: 10.1200/JCO.24.00285.
     PubMed     Abstract available
     
     
     
119. BRUNNER C, Arvandi M, Marth C, Egle D, et al
     Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study.
     J Clin Oncol. 2024 Aug 20:JCO2400171. doi: 10.1200/JCO.24.00171.
     PubMed     Abstract available
     
     
     
120. DILAWARI A, Buturla J, Osgood C, Gao X, et al
     US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations.
     J Clin Oncol. 2024 Aug 19:JCO2400427. doi: 10.1200/JCO.24.00427.
     PubMed     Abstract available
     
     
     
121. REEDER-HAYES KE, Jackson BE, Kuo TM, Baggett CD, et al
     Structural Racism and Treatment Delay Among Black and White Patients With Breast Cancer.
     J Clin Oncol. 2024 Aug 6:JCO2302483. doi: 10.1200/JCO.23.02483.
     PubMed     Abstract available
     
     
     
122. O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al
     Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis.
     J Clin Oncol. 2024;42:2645-2659.
     PubMed     Abstract available
     
     
     July 2024
123. PATEL BK, Carnahan MB, Northfelt D, Anderson K, et al
     Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.
     J Clin Oncol. 2024 Jul 26:JCO2202819. doi: 10.1200/JCO.22.02819.
     PubMed     Abstract available
     
     
     
124. KOK M, Gielen RJ, Adams S, Lennerz JK, et al
     Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.
     J Clin Oncol. 2024 Jul 22:JCO2400372. doi: 10.1200/JCO.24.00372.
     PubMed    
     
     
     
125. MATIKAS A, Mobus V, Greil R, Andersson A, et al
     Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
     J Clin Oncol. 2024 Jul 17:JCO2400178. doi: 10.1200/JCO.24.00178.
     PubMed     Abstract available
     
     
     
126. KATZ SJ, Abrahamse P, Furgal A, Hodan R, et al
     Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
     J Clin Oncol. 2024 Jul 15:JCO2400122. doi: 10.1200/JCO.24.00122.
     PubMed     Abstract available
     
     
     
127. OKEYA A, Shimomura A, Kitagawa D, Shimizu C, et al
     Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?
     J Clin Oncol. 2024 Jul 11:JCO2400992. doi: 10.1200/JCO.24.00992.
     PubMed    
     
     
     
128. RAMCHAND SK, Ghasem-Zadeh A, Hoermann R, White S, et al
     Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial.
     J Clin Oncol. 2024 Jul 2:JCO2302309. doi: 10.1200/JCO.23.02309.
     PubMed     Abstract available
     
     
     June 2024
129. TARANTINO P, Tayob N, Villacampa G, Dang C, et al
     Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
     J Clin Oncol. 2024 Jun 27:JCO2302170. doi: 10.1200/JCO.23.02170.
     PubMed     Abstract available
     
     
     
130. SCHMIDT JA, Woolpert KM, Hjorth CF, Farkas DK, et al
     Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer.
     J Clin Oncol. 2024 Jun 25:JCO2302643. doi: 10.1200/JCO.23.02643.
     PubMed     Abstract available
     
     
     
131. KUSUMOTO M, Shimomura A, Shimizu C
     Shorter Duration of Trastuzumab Combined With Chemotherapy for Early Breast Cancer.
     J Clin Oncol. 2024 Jun 24:JCO2302407. doi: 10.1200/JCO.23.02407.
     PubMed    
     
     
     
132. CORTES J, Hurvitz SA, O'Shaughnessy J, Delaloge S, et al
     Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.
     J Clin Oncol. 2024 Jun 18:JCO2302036. doi: 10.1200/JCO.23.02036.
     PubMed     Abstract available
     
     
     
133. SANDOVAL JL, Franzoi MA, di Meglio A, Ferreira AR, et al
     Magnitude and Temporal Variations of Socioeconomic Inequalities in the Quality of Life After Early Breast Cancer: Results From the Multicentric French CANTO Cohort.
     J Clin Oncol. 2024 Jun 18:JCO2302099. doi: 10.1200/JCO.23.02099.
     PubMed     Abstract available
     
     
     
134. SOLDATO D, Michiels S, Havas J, Di Meglio A, et al
     Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer.
     J Clin Oncol. 2024 Jun 5:JCO2301959. doi: 10.1200/JCO.23.01959.
     PubMed     Abstract available
     
     
     
135. CHAVEZ-MACGREGOR M, Miao J, Pusztai L, Goetz MP, et al
     Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy +/- 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.
     J Clin Oncol. 2024 Jun 4:JCO2302344. doi: 10.1200/JCO.23.02344.
     PubMed     Abstract available
     
     
     
136. BOSTANY G, Chen Y, Francisco L, Dai C, et al
     Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors.
     J Clin Oncol. 2024 Jun 4:JCO2301779. doi: 10.1200/JCO.23.01779.
     PubMed     Abstract available
     
     
     
137. SCHNEIDER BP, Zhao F, Ballinger TJ, Garcia SF, et al
     ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
     J Clin Oncol. 2024 Jun 3:JCO2400526. doi: 10.1200/JCO.24.00526.
     PubMed     Abstract available
     
     
     
138. CHAPMAN JW, Bayani J, SenGupta S, Bartlett JMS, et al
     Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.
     J Clin Oncol. 2024 Jun 2:JCO2400835. doi: 10.1200/JCO.24.00835.
     PubMed     Abstract available
     
     
     
139. RECHT A
     Internal Mammary Node Irradiation Debate: Case Closed? Not Yet, and Maybe Never.
     J Clin Oncol. 2024;42:1871-1874.
     PubMed     Abstract available
     
     
     
140. SORSCHER S
     Omission of Radiotherapy for Women With Low-Risk Invasive Cancers That Have a Ductal Carcinoma In Situ Component.
     J Clin Oncol. 2024;42:1998.
     PubMed    
     
     
     May 2024
141. AZIM HA JR, Niman SM, Partridge AH, Demeestere I, et al
     Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.
     J Clin Oncol. 2024 May 29:JCO2302292. doi: 10.1200/JCO.23.02292.
     PubMed     Abstract available
     
     
     
142. LU YS, Bin Mohd Mahidin EI, Azim H, Eralp Y, et al
     Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer.
     J Clin Oncol. 2024 May 21:JCO2400144. doi: 10.1200/JCO.24.00144.
     PubMed     Abstract available
     
     
     
143. SANTHOSH A, Sharma A, Bakhshi S, Kumar A, et al
     Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
     J Clin Oncol. 2024;42:1821-1829.
     PubMed     Abstract available
     
     
     
144. FREEDMAN RA, Caswell-Jin JL, Hassett M, Somerfield MR, et al
     Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
     J Clin Oncol. 2024 May 20:JCO2400886. doi: 10.1200/JCO.24.00886.
     PubMed     Abstract available
     
     
     
145. RAPP SR, Dressler EV, Brown WM, Wade JL 3rd, et al
     Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116).
     J Clin Oncol. 2024 May 6:JCO2301100. doi: 10.1200/JCO.23.01100.
     PubMed     Abstract available
     
     
     April 2024
146. 
     Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Yea
     J Clin Oncol. 2024 Apr 30:JCO2400711. doi: 10.1200/JCO.24.00711.
     PubMed    
     
     
     
147. BARDIA A, Krop IE, Kogawa T, Juric D, et al
     Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
     J Clin Oncol. 2024 Apr 23:JCO2301909. doi: 10.1200/JCO.23.01909.
     PubMed     Abstract available
     
     
     
148. RIOS-HOYO A, Cobain E, Huppert LA, Beitsch PD, et al
     Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
     J Clin Oncol. 2024 Apr 9:JCO2302614. doi: 10.1200/JCO.23.02614.
     PubMed    
     
     
     
149. VALENZA C, Trapani D, Loibl S, Chia SKL, et al
     Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
     J Clin Oncol. 2024 Apr 3:JCO2301935. doi: 10.1200/JCO.23.01935.
     PubMed     Abstract available
     
     
     
150. MUTTER RW, Chauhan C, Goetz MP, Wright JL, et al
     Revisiting Combined Modality Therapy in Older Patients With Luminal Breast Cancer Through the Patient Lens.
     J Clin Oncol. 2024 Apr 2:JCO2302289. doi: 10.1200/JCO.23.02289.
     PubMed    
     
     
     March 2024
151. MARTIN M, Lim E, Chavez-MacGregor M, Bardia A, et al
     Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
     J Clin Oncol. 2024 Mar 27:JCO2301500. doi: 10.1200/JCO.23.01500.
     PubMed     Abstract available
     
     
     
152. MAYER EL, Ren Y, Wagle N, Mahtani R, et al
     PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Bre
     J Clin Oncol. 2024 Mar 21:JCO2301940. doi: 10.1200/JCO.23.01940.
     PubMed     Abstract available
     
     
     
153. SALTBAEK L, Bidstrup PE, Karlsen RV, Hoeg BL, et al
     Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial.
     J Clin Oncol. 2024 Mar 18:JCO2301447. doi: 10.1200/JCO.23.01447.
     PubMed     Abstract available
     
     
     
154. MANN GB, Rose AK, Zdenkowski N
     What About This IDEA: The PROSPECT That Occult Malignant Lesions May Explain Local Recurrences in Very Early Breast Cancer?
     J Clin Oncol. 2024 Mar 15:JCO2302729. doi: 10.1200/JCO.23.02729.
     PubMed    
     
     
     
155. BURSTEIN HJ, DeMichele A, Fallowfield L, Somerfield MR, et al
     Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
     J Clin Oncol. 2024 Mar 13:JCO2400248. doi: 10.1200/JCO.24.00248.
     PubMed     Abstract available
     
     
     
156. RADFORD J
     Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.
     J Clin Oncol. 2024 Mar 13:JCO2302763. doi: 10.1200/JCO.23.02763.
     PubMed    
     
     
     February 2024
157. MARS N, Kerminen S, Tamlander M, Pirinen M, et al
     Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.
     J Clin Oncol. 2024 Feb 29:JCO2300295. doi: 10.1200/JCO.23.00295.
     PubMed     Abstract available
     
     
     
158. BARDIA A, Rugo HS, Tolaney SM, Loirat D, et al
     Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
     J Clin Oncol. 2024 Feb 29:JCO2301409. doi: 10.1200/JCO.23.01409.
     PubMed     Abstract available
     
     
     
159. MAXWELL KN, Domchek SM
     Toward Application of Polygenic Risk Scores to Both Enhance and Deintensify Breast Cancer Screening.
     J Clin Oncol. 2024 Feb 29:JCO2400029. doi: 10.1200/JCO.24.00029.
     PubMed    
     
     
     
160. 
     Erratum: Pathologic Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes.
     J Clin Oncol. 2024 Feb 23:JCO2400317. doi: 10.1200/JCO.24.00317.
     PubMed    
     
     
     
161. WORIAX HE, Thomas SM, Plichta JK, Rosenberger LH, et al
     Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.
     J Clin Oncol. 2024 Feb 23:JCO2301199. doi: 10.1200/JCO.23.01199.
     PubMed     Abstract available
     
     
     October 2023
162. WILKINSON AN, Ellison LF, Billette JM, Seely JM, et al
     Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years.
     J Clin Oncol. 2023;41:4669-4677.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum